| Document |
Document Title |
|
JP2009046411A |
To provide an insect proof dye comprising an ingredient derived from an alkaloid having antimicrobial properties as an active ingredient and having high safety and excellent fastness.The insect proof dye is selected from the group repres...
|
|
JP2009507005A |
There are provided inter alia derivatives of a benzenoid ansamycin which contain a 1,4-dihydroxyphenyl moiety bearing at position 6 an amino carboxy substituent, in which position 2 and the carboxy substituent at position 6 are connected...
|
|
JP4218277B2 |
|
|
JP4213472B2 |
A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to ...
|
|
JP2009501234A |
The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinon...
|
|
JP4207574B2 |
Laurolactam having high quality is produced by reacting cyclododecanone with a hydroxylamine salt of a mineral acid, and converting the resultant cyclododecanoneoxime to laurolactam through the Beckmann rearrangement reaction, wherein a ...
|
|
JP2008308501A |
To provide new thalidomide derivative compounds having activity as anti-angiogenesis compounds.The compounds having the general structures have the anti-angiogenesis activity: wherein R1 is selected from the group consisting of H, halo, ...
|
|
JP2008543822A |
The invention relates inter alia to a compound of general formula (I) or (I'): wherein z is 1,2 or 4; X is -CO-Y k -(R 1 ) n or SO 2 -Y k -(R 1 ) n ; k is 0 or 1; Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantane...
|
|
JP4189867B2 |
This invention relates to a series of arylsubstituted piperazines, of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the al...
|
|
JP2008201757A |
To provide an efficient method for producing 8- to 15-membered, that is, medium- to multiple-membered ring compounds.The invention relates to a method for production of 8- to 15-membered ring compounds represented by general formula (I) ...
|
|
JP2008531708A |
A pharmaceutical formulation comprising 17-AAG in an amount from about 1 mg/mL to about 5 mg/mL dissolved in a vehicle comprising (i) a first component that is an aprotic, polar solvent in an amount between about 0.1 and about 10 volume ...
|
|
JP2008179605A |
To provide a method for commercially and efficiently manufacturing a lactam from a cycloalkane at a high yield using a catalyst being friendly to the environment.The method for manufacturing a lactam comprising a process A of synthesizin...
|
|
JP2008156277A |
To provide an industrial method for producing an 8-15C lactam compound in high efficiency at a low cost by allowing the rearrangement reaction of a cyclic oxime compound to proceed without generating a large amount of by-products such as...
|
|
JP2008519031A |
Novel method of treating chronic lymphocytic leukemia by the administering of HSP90 inhibitors, particularly ansamycins, more particularly I 7-allylamino-I 7-demethoxygetdanarnycin (17-AAG).
|
|
JP2008519031A5 |
|
|
JP4090514B2 |
The present invention relates to compounds of the formulaQ is selected from the group consisting ofG is selected from the group consisting of alkyl, substituted alkyl, substituted or unsubstituted aryl, heterocyclo,W is O or NR15;X is O ...
|
|
JP4071000B2 |
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR5, and the other substituents are as defined in the specification; an...
|
|
JP2008505984A |
Geldanamycin compounds having a structure according to formula I where Q1, L, L1, R5, R6, and R11 are as defined herein, are useful for treating a disease or disorder ameliorated by inhibiting the function of extracellular heat shock pro...
|
|
JP4046860B2 |
|
|
JP4043363B2 |
The present invention relates to alanine 2,6-dialkoxyphenyl ester derivatives having the general formula I The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these alanine 2,6-dialkox...
|
|
JP2008502595A |
The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R1, R2, R3 and R4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. T...
|
|
JP2008502726A |
Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components. The compounds are con...
|
|
JP2008500270A |
The present invention relates to substances capable of specifically inhibiting Gly-Pro-p-nitroanilide cleaving peptidases, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances o...
|
|
JP2008500370A |
Dictyostatin and its analogs show great promise as new anticancer agents. The present invention provides dictyostatin analogs, synthetic intermediates for the synthesis of dictyostatin analogs, and synthetic methods for the synthesis of ...
|
|
JP4029159B2 |
|
|
JP4011022B2 |
A novel polymer-supported arene-ruthenium complex represented by the following formula: , wherein A represents an organic polymer with a side chain containing an aromatic ring coordinated to Ru, X1 and X2 represent the same or different ...
|
|
JP2007530596A |
Geldanamycin derivatives that block the uPA-plasmin network and inhibit growth and invasion by glioblastoma cells and other tumors at femtomolar concentrations are potentially highly active anti-cancer drugs. GA and various 17-amino-17-d...
|
|
JP2007284415A |
To provide a process for producing an amide or a lactam by conducting rearrangement of an oxime compound to yield a corresponding amide or lactam, in which the amide or the lactam can be easily produced in a high yield without generating...
|
|
JP3955211B2 |
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I:wherein X, Y, and Z are O, S, or NR<4>, and the other substituents are as defined in the specification; ...
|
|
JP3955180B2 |
The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, ...
|
|
JPWO2005061461A1 |
The present invention has a formula (I) useful as a pharmaceutical product such as an antitumor agent.(In the formula, R2Represents hydrogen or methyl, R11And R18Represents the same or different hydroxy, substituted or unsubstituted lowe...
|
|
JP3924124B2 |
The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, ...
|
|
JP2007126460A |
To provide a compound and a composition effective for inhibiting the activity of a CETP [cholesterol ester transfer protein (plasma lipid transfer protein-1)] and useful for treating especially atherosclerosis and other coronary arterial...
|
|
JP2007112804A |
To provide substituted aryl and heteroaryl (R)-chiral halogenated 1-substituted amino-(n+1)-alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and a composition of the com...
|
|
JP2007502278A |
The present invention is directed to compounds of formula I which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheime...
|
|
JP2006523213A |
Embodiments of this invention provide novel peptidomimetics that contain a macrocycle, an embodiment of which is 2S,9′S,12′S)-2-{[(1′,4′-Diaza-2′-oxobicyclo[7.3.0]
dodecyl)-12′-carbonyl]amino}-1,5-pentanedioic acid trifluoroa...
|
|
JP3819759B2 |
To provide a compound having excellent choline esterase inhibitory activity and monoamine intake inhibitory activity, thus useful as a prophylactic/ therapeutic agent for senile dementia. This compound (a salt thereof) is shown by the fo...
|
|
JP2006514939A |
Methods of making substituted phenylalkynes of formula (I).
|
|
JP2006056811A |
To provide a method for efficiently manufacturing an amide compound by a Beckmann rearrangement reaction of an oxime compound in a liquid phase without by-producing ammonium sulfate.In the manufacturing method of the corresponding amide ...
|
|
JP3726980B2 |
To obtain the subject new compound having an antitumor activity from a specific actinomyces belonging to the genus Streptomyces and collected and separated from a specified soil. A compound of formula I (R is a group of formula II), e.g....
|
|
JP3721388B2 |
To provide a new optically active amine having a 9-membered ring having a plane asymmetry stable at room temperature as the sole asymmetry, completely transferring the plane asymmetry of the amine to the central asymmetry of a rearranged...
|
|
JP2005530689A |
Ansamycins and methods of preparing and using the same are described. At least some of these ansamycins exhibit one or more of improved aqueous formulation ability, chemical stability, and bioavailability. Some of the derivatives describ...
|
|
JP2005529223A |
A polymerisation inhibitor comprising a non-hindered cyclic hydroxylamine either alone or in combination with an additional inhibitor.
|
|
JP2005255661A |
To obtain a transition metal complex comprising a 9-membered ring amine having plane asymmetry stable at a room temperature as an asymmetric ligand and to provide a method for producing the same.The 9-membered ring amine-transition metal...
|
|
JP2005255658A |
To provide a method for producing a quaternary ammonium salt of plane asymmetry containing various substituent groups, which has hitherto no example of reports, from a medium-ring amine of plane asymmetry found by a discoverer and a func...
|
|
JP2005255659A |
To provide a method for producing an amine of plane asymmetry with a reactive functional group, having more general purpose properties and a method for producing an optically active amine by conversion reaction of an amine of plane asymm...
|
|
JP2005520795A |
Ligand binding assays as applied to HSP90s as receptors or ligands, and reagents useful therefore, are described and claimed, as are methods of assaying for HSP90 modulators and methods of using the resulting products identified thereby.
|
|
JPWO2003068753A1 |
For stress, which contains a compound represented by the general formula (I) (the symbol in the formula is as described in the specification), a mitochondrial benzodiazepine receptor (MBR) antagonist composed of the compound, and the com...
|
|
JP2005515164A |
The present invention provides compounds, methods for their preparation, and intermediates thereof, and methods for the use of those compounds in the treatment of diseases or conditions characterized by unwanted cell proliferation or hyp...
|
|
JPWO2003053927A1 |
In the formula, n represents an integer of 1 to 8, R1 represents a hydrogen atom or a C1-10 alkyl group, A represents a CH or nitrogen atom, Ar1 represents a phenyl group or a substituted phenyl group, and Y represents a phenyl group or ...
|
